AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

Arab Finance: AstraZeneca Egypt is planning to inject $50 million into new investments in Egypt, equivalent to nearly 50% of the company’s capital, the firm’s Country President Hatem Werdany stated.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...

As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could ...